Foamix Pharmaceuticals Company Profile (NASDAQ:FOMX)

About Foamix Pharmaceuticals (NASDAQ:FOMX)

Foamix Pharmaceuticals logoFoamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FOMX
  • CUSIP: N/A
  • Web: www.foamix.co.il
Capitalization:
  • Market Cap: $205.84 million
  • Outstanding Shares: 37,426,000
Average Prices:
  • 50 Day Moving Avg: $4.90
  • 200 Day Moving Avg: $5.28
  • 52 Week Range: $4.03 - $11.27
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.73
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.76 million
  • Price / Sales: 35.74
  • Book Value: $2.70 per share
  • Price / Book: 2.04
Profitability:
  • EBIDTA: ($47,960,000.00)
  • Net Margins: -823.74%
  • Return on Equity: -39.20%
  • Return on Assets: -36.76%
Debt:
  • Current Ratio: 9.04%
  • Quick Ratio: 9.04%
Misc:
  • Average Volume: 113,850 shs.
  • Beta: 1.66
  • Short Ratio: 11.78
 

Frequently Asked Questions for Foamix Pharmaceuticals (NASDAQ:FOMX)

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

How were Foamix Pharmaceuticals' earnings last quarter?

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) posted its earnings results on Tuesday, August, 8th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.05. The company had revenue of $0.80 million for the quarter, compared to analysts' expectations of $1.50 million. Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The firm's quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) EPS. View Foamix Pharmaceuticals' Earnings History.

When will Foamix Pharmaceuticals make its next earnings announcement?

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Foamix Pharmaceuticals.

Where is Foamix Pharmaceuticals' stock going? Where will Foamix Pharmaceuticals' stock price be in 2017?

2 brokerages have issued 1-year price targets for Foamix Pharmaceuticals' shares. Their predictions range from $9.00 to $12.00. On average, they expect Foamix Pharmaceuticals' share price to reach $10.50 in the next twelve months. View Analyst Ratings for Foamix Pharmaceuticals.

Who are some of Foamix Pharmaceuticals' key competitors?

Who owns Foamix Pharmaceuticals stock?

Foamix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (4.03%), AXA (2.53%), Tekla Capital Management LLC (2.50%), Vivo Capital LLC (2.30%), Marshall Wace North America L.P. (1.70%) and Senzar Asset Management LLC (1.53%). View Institutional Ownership Trends for Foamix Pharmaceuticals.

Who sold Foamix Pharmaceuticals stock? Who is selling Foamix Pharmaceuticals stock?

Foamix Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Menora Mivtachim Holdings LTD., Goldman Sachs Group Inc., Jennison Associates LLC and Senzar Asset Management LLC. View Insider Buying and Selling for Foamix Pharmaceuticals.

Who bought Foamix Pharmaceuticals stock? Who is buying Foamix Pharmaceuticals stock?

Foamix Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bank of New York Mellon Corp, AXA, PDT Partners LLC, DAFNA Capital Management LLC, UBS Asset Management Americas Inc. and Franklin Resources Inc.. View Insider Buying and Selling for Foamix Pharmaceuticals.

How do I buy Foamix Pharmaceuticals stock?

Shares of Foamix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foamix Pharmaceuticals' stock price today?

One share of Foamix Pharmaceuticals stock can currently be purchased for approximately $5.50.


MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Foamix Pharmaceuticals (NASDAQ:FOMX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.50 (90.91% upside)

Analysts' Ratings History for Foamix Pharmaceuticals (NASDAQ:FOMX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/24/2017HC WainwrightInitiated CoverageBuy -> Buy$12.00HighView Rating Details
7/19/2017Credit Suisse GroupReiterated RatingBuy$9.00LowView Rating Details
8/13/2016GuggenheimReiterated RatingBuy$10.00 -> $20.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)
Earnings by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)
Earnings History by Quarter for Foamix Pharmaceuticals (NASDAQ FOMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.43)N/AView Earnings Details
8/8/2017Q2($0.39)($0.44)$1.50 million$0.80 millionViewListenView Earnings Details
2/21/2017Q416($0.26)($0.31)$1.49 millionViewN/AView Earnings Details
8/10/2016Q216($0.25)($0.27)$1.10 million$1.50 millionViewListenView Earnings Details
5/10/2016Q1($0.23)($0.15)$0.53 million$0.75 millionViewListenView Earnings Details
11/11/2015Q315($0.20)($0.11)$1.50 million$0.02 millionViewListenView Earnings Details
8/19/2015Q215($0.14)($0.18)$1.00 million$0.11 millionViewListenView Earnings Details
5/12/2015Q1($0.12)($0.14)$1.00 million$0.45 millionViewN/AView Earnings Details
4/15/2015($0.12)($0.18)ViewN/AView Earnings Details
11/14/2014Q314($0.07)($0.12)$1.00 million$0.42 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Foamix Pharmaceuticals (NASDAQ:FOMX)
Current Year EPS Consensus Estimate: $-1.53 EPS
Next Year EPS Consensus Estimate: $-0.96 EPS

Dividends

Dividend History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Foamix Pharmaceuticals (NASDAQ:FOMX)
Latest Headlines for Foamix Pharmaceuticals (NASDAQ:FOMX)
Source:
DateHeadline
finance.yahoo.com logoFoamix Pharmaceuticals Ltd. :FOMX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 6:30 PM
finance.yahoo.com logoOWC Pharma Issues Chairman's Letter to Shareholders
finance.yahoo.com - September 14 at 7:23 PM
americanbankingnews.com logoHC Wainwright Begins Coverage on Foamix Pharmaceuticals Ltd. (FOMX)
www.americanbankingnews.com - August 24 at 8:06 AM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 12:00 AM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd. (FOMX) Posts Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - August 9 at 10:48 PM
finance.yahoo.com logoFoamix Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 8 at 6:28 PM
finance.yahoo.com logoFoamix reports 2Q loss
finance.yahoo.com - August 8 at 6:28 PM
finance.yahoo.com logoFoamix Announces Dosing of First Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
finance.yahoo.com - August 3 at 3:59 PM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:26 AM
finance.yahoo.com logoFoamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for August 9
finance.yahoo.com - July 26 at 7:22 PM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd. (FOMX) Receives "Buy" Rating from Credit Suisse Group
www.americanbankingnews.com - July 19 at 9:18 PM
finance.yahoo.com logoFoamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer
finance.yahoo.com - June 29 at 9:07 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 2017 BIO International Convention
finance.yahoo.com - June 15 at 7:25 PM
finance.yahoo.com logoFoamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5%
finance.yahoo.com - June 12 at 6:06 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 6:01 PM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd (FOMX) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 16 at 10:40 PM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd (FOMX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 14 at 2:36 PM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 10:24 PM
finance.yahoo.com logoInvestor Network: Foamix Pharmaceuticals Ltd. to Host Earnings Call
finance.yahoo.com - May 10 at 9:32 AM
americanbankingnews.com logoZacks Investment Research Lowers Foamix Pharmaceuticals Ltd (FOMX) to Hold
www.americanbankingnews.com - May 9 at 7:30 PM
marketbeat.com logoFoamix reports 1Q loss
marketbeat.com - May 9 at 6:01 PM
finance.yahoo.com logoFoamix Reports First Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - May 9 at 5:08 PM
americanbankingnews.com logoFoamix Pharmaceuticals (FOMX) Receiving Somewhat Negative News Coverage, Report Finds
www.americanbankingnews.com - May 3 at 9:49 AM
finance.yahoo.com logoFoamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe Acne
finance.yahoo.com - May 1 at 5:03 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - April 27 at 5:49 PM
finance.yahoo.com logoFoamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Tuesday, May 10
finance.yahoo.com - April 26 at 8:07 PM
americanbankingnews.com logoFoamix Pharmaceuticals (FOMX) Earns Daily Coverage Optimism Rating of -0.27
www.americanbankingnews.com - April 26 at 11:10 AM
americanbankingnews.com logoFoamix Pharmaceuticals (FOMX) Receives News Impact Rating of -0.14
www.americanbankingnews.com - April 18 at 9:59 AM
americanbankingnews.com logoZacks: Brokerages Expect Foamix Pharmaceuticals Ltd (FOMX) Will Announce Quarterly Sales of $0.00
www.americanbankingnews.com - April 12 at 1:42 PM
americanbankingnews.com logoFoamix Pharmaceuticals Ltd (FOMX) PT Lowered to $9.00 at Credit Suisse Group AG
www.americanbankingnews.com - April 3 at 11:44 AM
investopedia.com logoFoamix Acne Drug Fails Late-Stage Study (FOMX)
www.investopedia.com - March 28 at 9:56 PM
americanbankingnews.com logoCredit Suisse Group AG Lowers Foamix Pharmaceuticals Ltd (FOMX) Price Target to $9.00
www.americanbankingnews.com - March 28 at 10:44 AM
us.rd.yahoo.com logoFoamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
us.rd.yahoo.com - March 27 at 11:40 AM
investopedia.com logoFoamix Acne Drug Fails Late-Stage Study
www.investopedia.com - March 27 at 11:40 AM
seekingalpha.com logoHigh-Potential Pipeline And Sufficient Cash Make Foamix Pharmaceuticals A Solid Buy For 2017
seekingalpha.com - March 23 at 5:46 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
finance.yahoo.com - March 8 at 6:05 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the ROTH Capital Partners 29th Annual Growth Conference
finance.yahoo.com - March 7 at 11:34 AM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the Cowen & Company 37th Annual Healthcare Conference
finance.yahoo.com - February 27 at 7:15 PM
finance.yahoo.com logoFOAMIX PHARMACEUTICALS LTD. Financials
finance.yahoo.com - February 25 at 5:05 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation Forum
finance.yahoo.com - February 23 at 5:17 PM
seekingalpha.com logoFoamix Pharmaceuticals' (FOMX) CEO Dov Tamarkin on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 22 at 10:34 PM
finance.yahoo.com logoEdited Transcript of FOMX earnings conference call or presentation 22-Feb-17 1:30pm GMT
finance.yahoo.com - February 22 at 10:34 PM
biz.yahoo.com logoQ4 2016 Foamix Pharmaceuticals Ltd Earnings Release - After Market Close
biz.yahoo.com - February 22 at 10:45 AM
finance.yahoo.com logoFoamix Reports Year End 2016 Financial Results and Provides Business Update
finance.yahoo.com - February 22 at 10:45 AM
finance.yahoo.com logoCoverage initiated on Foamix by Credit Suisse
finance.yahoo.com - February 16 at 5:14 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22
finance.yahoo.com - February 7 at 6:30 PM
finance.yahoo.com logoFoamix Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 11:19 AM
finance.yahoo.com logoBlog Coverage Egalet Announced Positive Results from Human Abuse Potential Study of Egalet-002
finance.yahoo.com - December 19 at 9:16 AM
us.rd.yahoo.com logoFoamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101
us.rd.yahoo.com - November 29 at 5:11 PM
us.rd.yahoo.com logoFoamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101
us.rd.yahoo.com - November 29 at 5:11 PM

Social

Chart

Foamix Pharmaceuticals (FOMX) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff